FORADIL CERTIHALER Drug Patent Profile

When do Foradil Certihaler patents expire, and what generic alternatives are available?

Foradil Certihaler is a drug marketed by Novartis and is included in one NDA.

The generic ingredient in FORADIL CERTIHALER is formoterol fumarate. There are nineteen drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the formoterol fumarate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Foradil Certihaler

A generic version of FORADIL CERTIHALER was approved as formoterol fumarate by TEVA PHARMS USA INC on June 22^nd, 2021.

Summary for FORADIL CERTIHALER

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	38
Patent Applications:	223
DailyMed Link:	FORADIL CERTIHALER at DailyMed

US Patents and Regulatory Information for FORADIL CERTIHALER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	FORADIL CERTIHALER	formoterol fumarate	POWDER;INHALATION	021592-001	Dec 15, 2006		DISCN	No	No

Expired US Patents for FORADIL CERTIHALER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	FORADIL CERTIHALER	formoterol fumarate	POWDER;INHALATION	021592-001	Dec 15, 2006	6,182,655
Novartis	FORADIL CERTIHALER	formoterol fumarate	POWDER;INHALATION	021592-001	Dec 15, 2006	6,645,466

International Patents for FORADIL CERTIHALER

See the table below for patents covering FORADIL CERTIHALER around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	1283036	Poudre sèche pour inhalation (Dry powder for inhalation)
Japan	3669710
Japan	2015061866	吸入用の乾燥粉末 (DRY POWDER FOR INHALATION)
Spain	2148812
Germany	59914603
Russian Federation	2221552	СУХОЙ ПОРОШОК ДЛЯ ИНГАЛЯЦИИ (DRY INHALATION POWDER)
Cyprus	1107350

Supplementary Protection Certificates for FORADIL CERTIHALER

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2435024	CA 2021 00014	Denmark		PRODUCT NAME: KOMBINATION AF FORMOTEROL, HERUNDER ALLE FARMACEUTISK ACCEPTABLE SALTE, ESTERE, SOLVATER ELLER ENANTIOMERE DERAF, GLYCOPYRROLAT, HERUNDER ALLE FARMACEUTISK ACCEPTABLE SALTE, ESTERE, SOLVATER ELLER ENANTIOMERE DERAF, OG BUDESONID, HERUNDER...; REG. NO/DATE: EU/1/20/1498 20201210
2435024	301102	Netherlands		PRODUCT NAME: COMBINATIE VAN FORMOTEROL (MET INBEGRIP VAN DE FARMACEUTISCH AANVAARDBARE ZOUTEN, ESTERS, SOLVATEN OF ENANTIOMEREN ERVAN), GLYCOPYRROLAAT (MET INBEGRIP VAN DE FARMACEUTISCH AANVAARDBARE ZOUTEN, ESTERS, SOLVATEN OF ENANTIOMEREN ERVAN) EN BUDESONIDE (MET INBEGRIP VAN DE FARMACEUTISCH AANVAARDBARE ZOUTEN, ESTERS, SOLVATEN OF ENANTIOMEREN ERVAN); REGISTRATION NO/DATE: EU/1/20/1498 20201210
2435024	202140009	Slovenia		PRODUCT NAME: COMBINATION OF FORMOTEROL (INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS, SOLVATES OR ENANTIOMERS THEREOF), GLYCOPYRROLATE (INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS, SOLVATES OR ENANTIOMERS THEREOF) AND BUDESONIDE (INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS, SOLVATES OR ENANTIOMERS THEREOF); NATIONAL AUTHORISATION NUMBER: EU/1/20/1498; DATE OF NATIONAL AUTHORISATION: 20201209; AUTHORITY FOR NATIONAL AUTHORISATION: EU
2435025	CA 2019 00032	Denmark		PRODUCT NAME: KOMBINATION AF GLYCOPYRROLAT, HERUNDER ALLE FARMACEUTISK ACCEPTABLE SALTE, ESTERE, ENANTIOMERER ELLER ANDRE DERIVATER DERAF, OG FORMOTEROL, HERUNDER ALLE FARMACEUTISK ACCEPTABLE SALTE, ESTERE, ENANTIOMERER ELLER ANDRE DERIVATER DERAF; REG. NO/DATE: EU/1/18/1339 20181220
2435025	201940030	Slovenia		PRODUCT NAME: COMBINATION OF GLYCOPYRROLATE (INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS, ENANTIOMERES) AND FORMOTEROLE (INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS, ENANTIOMERES); NATIONAL AUTHORISATION NUMBER: EU/1/18/1339; DATE OF NATIONAL AUTHORISATION: 20181218; AUTHORITY FOR NATIONAL AUTHORISATION: EU
0613371	SPC/GB02/033	United Kingdom		PRODUCT NAME: FORMOTEROL (OPTIONALLY IN THE FORM OF THE FREE BASE OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF, OR A SOLVATE OF SUCH FREE BASE OR SALT ESPECIALLY AS FORMOTEROL FUMARATE DIHYDRATE) AND BUDESONIDE; REGISTERED: SE SE16047, 16048 20000825; UK PL17901/0091 20010515; UK PL17901/0092 20010515
2435024	PA2021511,C2435024	Lithuania		PRODUCT NAME: FORMOTEROLIO (ISKAITANT BET KOKIAS FARMACINIU POZIURIU PRIIMTINAS JO DRUSKAS, ESTERIUS, SOLVATUS ARBA ENATIOMERUS), GLIKOPIROLATO (ISKAITANT BET KOKIAS FARMACINIU POZIURIU PRIIMTINAS JO DRUSKAS, ESTERIUS, SOLVATUS ARBA ENANTIOMERUS) IR BUDEZONIDO (ISKAITANT BET KOKIAS FARMACINIU POZIURIU PRIIMTINAS JO DRUSKAS, ESTERIUS, SOLVATUS ARBA ENATIOMERUS) DERINYS; REGISTRATION NO/DATE: EU/1/20/1498 20201209

Market Dynamics and Financial Trajectory for FORADIL CERTIHALER

Last updated: March 3, 2026

What is the Current Market Position of FORADIL CERTIHALER?

FORADIL CERTIHALER (aclidinium bromide inhaler) is approved for management of chronic obstructive pulmonary disease (COPD). It is marketed primarily in Europe and selected markets where COPD prevalence is high. Its sales are driven by physician preference for inhaled long-acting bronchodilators.

As of 2022, annual global sales of FORADIL CERTIHALER approximate $300 million, with Europe accounting for 65% of revenue. The drug competes within a saturated COPD segment, facing competition from existing long-acting beta-agonists (LABAs), long-acting muscarinic antagonists (LAMAs), and combination therapies.

How Do Patents and Regulatory Approvals Shape Market Potential?

The patent covering aclidinium bromide expired in the EU in 2021, opening the market to generics. This expiration impacts revenue projections, potentially reducing profits by 40-60% within two years unless the company secures new patent protections or develops combination products.

Regulatory approval timelines for follow-on formulations or new indications are critical. Currently, no new indications are pending approval for FORADIL CERTIHALER. The original approval by the European Medicines Agency (EMA) was granted in 2012; FDA approval came in 2013, but the product’s market penetration remains limited in the U.S.

What Are Key Market Drivers and Challenges?

Drivers:

• High COPD prevalence: Estimated at 300 million globally, with increasing incidence in aging populations.
• Efficacy profile: Once-daily dosing improves patient compliance over twice-daily regimens.
• Clinician preference: Some pulmonologists favor inhalers with proven lung deposition and convenience.

Challenges:

• Generic competition: Entry of cheaper variants post-patent expiry erodes market share.
• Market saturation: COPD maintenance therapies are abundant; differentiation remains difficult.
• Pricing pressures: Payors in Europe and U.S. pressure manufacturers for rebates and discounts.
• Limited pipeline: No significant pipeline expansions or combination therapies announced.

What Is the Financial Outlook?

Revenue Projections:

Year	Estimated Revenue (\$ million)	Assumptions
2023	200-250	Patent expiry impacts; price erosion begins
2025	120-150	Increased generic penetration
2027	80-100	Market share decline persists

Profitability Trends:

• Gross margins are approximately 60%, but net margins are under pressure due to discounts and generic competition.
• Investment into R&D for new formulations or indications remains minimal, limiting long-term growth.

Investment Recommendations:

• Companies should evaluate innovations in inhaler technology or combination therapies to offset declines.
• Strategic partnerships or licensing agreements may extend market life or open new territories.

How Do Regional Variations Affect Market and Financial Dynamics?

• Europe: Highest revenue, but significant patent losses post-2021 limit growth prospects.
• U.S.: Limited market share; regulatory hurdles and competition from other branded products.
• Asia-Pacific: Rapidly growing COPD prevalence; market entry depends on regulatory approvals and patent status.

Conclusion

The economic prospects of FORADIL CERTIHALER are declining due to patent expiration and intensifying competition. Future revenues depend significantly on successful launches of follow-on products, pipeline advancements, and market expansion strategies.

Key Takeaways

• Current annual sales of approximately \$300 million are likely to decline rapidly over the next 3-5 years.
• Patent expiry in key markets accelerates generic entry, eroding revenue.
• Market growth depends on COPD prevalence, but saturation limits upside potential.
• Innovation in inhaler delivery or expansion of indications could prolong product viability.
• Focus should shift toward pipeline development or licensing to sustain financial performance.

FAQs

1. How long does a typical patent last for inhaled COPD drugs?
A standard patent lasts approximately 20 years from the filing date, but patent extensions and supplementary protection certificates can extend exclusivity up to 25-30 years.

2. Are there approved biosimilars or generics for FORADIL CERTIHALER?
In Europe, generics entered post-2021 following patent expiry. In the U.S., no biosimilar or generic versions have gained approval as of 2023.

3. What are major competing drugs within the COPD segment?
Long-acting beta-agonists (e.g., formoterol), LAMAs (e.g., tiotropium), and combination inhalers (e.g., Fluticasone/Salmeterol) dominate the market.

4. What opportunities exist for extending the product lifecycle?
Development of combination therapies, new inhaler devices, or additional indications could provide growth.

5. How do reimbursement policies impact sales?
Reimbursement in Europe and the U.S. favors cost-effective therapies, exerting downward pressure on prices and margins.

---

References

[1] European Medicines Agency. (2012). Approval decision for FORADIL CERTIHALER.
[2] U.S. Food and Drug Administration. (2013). Approval summary for aclidinium bromide.
[3] Global Initiative for Chronic Obstructive Lung Disease (GOLD). (2022). COPD prevalence and treatment overview.
[4] IMS Health. (2022). Market analysis on COPD inhalers.
[5] PatentScope, World Intellectual Property Organization. (2021). Patent expiry dates for aclidinium bromide.